One of the world's largest kidney-care providers, DaVita runs thousands of dialysis centers across the US and in over a dozen other countries, treating patients with failing kidneys. Born in 1994 as Total Renal Care, it was renamed DaVita in 2000 after near-collapse; the name comes from an Italian phrase meaning "to give life." Its employees call themselves "teammates" and the company "the Village," a culture built during a celebrated turnaround.
DaVita enters Ninth Amendment adding $500M term loan B facility
DaVita Inc. entered a Ninth Amendment to its August 2019 Credit Agreement on June 8, 2026, adding $500 million in incremental Tranche B-2 Term Loans.
Show detailsHide details
The Tranche B-2 Term Facility matures in May 2031 and bears interest at Term SOFR plus 175 basis points or Base Rate plus 75 basis points.
Proceeds will repay part of DaVita's senior secured revolving loan facility (due November 2030), pay related fees, and fund general corporate purposes.
At the June 4, 2026 Annual Meeting, stockholders elected nine directors, ratified KPMG as auditor, and approved executive compensation on an advisory basis.
The annual meeting had 59,865,902 shares represented, about 91% of outstanding shares as of the April 9, 2026 record date.
1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits
Consolidated revenues were $3.416 billion for Q1 2026, with operating income of $482 million (14.1% margin).
Show detailsHide details
Diluted EPS from continuing operations was $2.87, up from $2.00 in Q1 2025.
Operating cash flow was $321 million and free cash flow was $140 million for the quarter.
Repurchased 3.0 million shares at an average price of $133.70 per share during Q1; 2.0 million more shares repurchased after quarter-end through May 5.
Raised 2026 guidance for adjusted operating income to $2,150-$2,250 million and adjusted diluted EPS to $14.10-$15.20.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
DaVita enters $3.5B new credit facilities to refinance existing debt
DaVita Inc. entered an Eighth Amendment to its 2019 Credit Agreement on November 24, 2025.
Show detailsHide details
The amendment establishes a new $2 billion secured term loan A facility and a new $1.5 billion secured revolving credit facility.
Proceeds will refinance outstanding amounts under DaVita's prior ~$1.95 billion term loan and $1.5 billion revolving credit facility, both maturing in April 2028.
The new facilities bear interest at variable rates based on Term SOFR, EURIBOR, or Daily Simple SONIA, with an initial Applicable Margin of 150 basis points (50 bps for Base Rate loans).
The new term loan amortizes quarterly starting March 31, 2026, with the balance due at maturity in five years.
1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 9.01 Financial Statements and Exhibits
DaVita board adds $2B to share repurchase authorization on Aug. 20, 2025
The new authorization is separate from the existing program authorized on September 5, 2024; neither has an expiration date.
Show detailsHide details
DaVita Inc.'s board increased its share repurchase program by $2,000,000,000 in additional authorization on August 20, 2025.
Repurchases may occur in open market or private transactions, including under the April 30, 2024 share repurchase agreement with Berkshire Hathaway Inc.
The company is not obligated to purchase any shares and may suspend, discontinue, or adjust the authorizations at any time.
Repurchases are subject to limitations under the company's current senior secured credit facilities.